NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
11/21/2023
Back to search
Official data from USPTO
TPD2
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
23
Latest update
11/21/2023
Trademark type
Combined
Nice classes
5
Filing date
11/27/2021
Registration date
11/21/2023
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
11/21/2023
Last transaction
11/21/2023
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
Drawing code
5
Owner type
03
Owner location
Daejeon, KR
Examiner
HARPER, HANNAH
Law office
N90
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of the letters "TPD" followed by a superscripted "2".
Holders and representatives
Holders
Orum Therapeutics, Inc.
Representatives
Steven J. Hultquist HULTQUIST, PLLC
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
biopharmaceuticals for the treatment of cancer; biological preparations for the treatment of cancer; pharmaceutical preparations and substances for the prevention of cancer; pharmaceutical preparations for the treatment of cancer; pharmaceutical preparations and compositions for the treatment and prevention of cancer; anti-cancer preparations; pharmaceutical compounds for treating cancer; drugs for medical purposespharmaceutical drugs for the prevention and treatment of cancer; medicines for human purposesfor the prevention and treatment of cancer; antibodies for medical purposesfor the treatment of cancer; biological preparations for medical purposesbiological preparations for the treatment of cancer; pharmaceutical preparations for veterinary useveterinary pharmaceutical preparations for the treatment of cancer; biological preparations for medical and veterinary purposesfor the prevention and treatment of cancer; antibody drug conjugates for medical purposesfor the prevention and treatment of cancer
Publications
History of USPTO decisions and trademark events.
23 publications found
R.PR
REGISTERED-PRINCIPAL REGISTER
11/21/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
09/05/2023
PUBO
PUBLISHED FOR OPPOSITION
09/05/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
08/16/2023
OTHE
CASE RETURNED TO EXAMINATION
08/01/2023
IUCN
NOTICE OF ALLOWANCE CANCELLED
07/27/2023
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
07/19/2023
PCBG
PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
07/19/2023
APET
ASSIGNED TO PETITION STAFF
07/12/2023
TPAD
TEAS PETITION TO AMEND BASIS RECEIVED
06/28/2023
EXRA
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
02/16/2023
EX1G
SOU EXTENSION 1 GRANTED
02/14/2023
EXT1
SOU EXTENSION 1 FILED
02/14/2023
EEXT
SOU TEAS EXTENSION RECEIVED
02/14/2023
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
08/16/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
06/21/2022
PUBO
PUBLISHED FOR OPPOSITION
06/21/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
06/01/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
05/16/2022
DOCK
ASSIGNED TO EXAMINER
05/03/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/01/2021
NWAP
NEW APPLICATION ENTERED
12/01/2021
Continuous trademark protection
Get notified about every new filing that threatens TPD2 or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.